Disorders of gut-brain interaction: Highly prevalent and burdensome yet under-taught within medical education.
DGBI
FGID
IBS
constipation
disorders of gut-brain interaction
functional gastrointestinal disorders
irritable bowel syndrome
motility
motility disorders
Journal
United European gastroenterology journal
ISSN: 2050-6414
Titre abrégé: United European Gastroenterol J
Pays: England
ID NLM: 101606807
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
05
05
2022
accepted:
15
06
2022
pubmed:
6
7
2022
medline:
23
9
2022
entrez:
5
7
2022
Statut:
ppublish
Résumé
To determine the population prevalence and associated health impairment of disorders of gut-brain interaction (DGBI) across Great Britain, and the emphasis placed upon them within medical education. An Internet-based cross-sectional health survey was completed by 1906 general population adults across Great Britain without self-reported organic GI disease. The survey enquired for demographics, symptom-based criteria for Rome IV DGBI, healthcare use, non-GI somatic symptoms, and quality of life. As a separate analysis, we evaluated which DGBI are considered core knowledge at undergraduate medical school level and post-graduate specialization level for Gastroenterologists and General Practitioners. The overall prevalence of DGBI across Great Britain was 37%, being similar for England (37%), Scotland (33%), and Wales (36%); p = 0.66. There was no difference between English regions (range 33%-43%, p = 0.26). The prevalence of DGBI was highest in those aged 18-40 years (40%), then 40-64 years (37%), and least amongst those ≥65 years (29%); p < 0.001. The most common DGBI were bowel disorders (30%), followed by gastroduodenal (10.5%), anorectal (8.1%) and oesophageal disorders (6.2%). Individuals with DGBI were significantly more likely than those without DGBI to have increased GI-related healthcare visits, medication use, surgical interventions, non-GI somatic symptoms, and reduced quality of life. One-in-three people with DGBI had multiple GI organ regions involved and this correlated with increased health impairment (p < 0.001). The only DGBI mentioned across all medical training curricula is irritable bowel syndrome, while the General Practitioner and Gastroenterology Curricula also recognise the outdated term non-ulcer dyspepsia (as opposed to functional dyspepsia). The 2010 Gastroenterology Curriculum also includes functional constipation and disordered defecation, with the incoming 2022 iteration adding in functional upper GI syndromes, functional abdominal pain, and opioid-induced GI disturbances. Disorders of gut-brain interaction are common across Great Britain and incur substantial health impairment. However, they are generally under-taught within the British medical education system. Increasing awareness and education of disorders of gut-brain interaction might improve patient outcomes.
Sections du résumé
BACKGROUND AND OBJECTIVE
To determine the population prevalence and associated health impairment of disorders of gut-brain interaction (DGBI) across Great Britain, and the emphasis placed upon them within medical education.
METHODS
An Internet-based cross-sectional health survey was completed by 1906 general population adults across Great Britain without self-reported organic GI disease. The survey enquired for demographics, symptom-based criteria for Rome IV DGBI, healthcare use, non-GI somatic symptoms, and quality of life. As a separate analysis, we evaluated which DGBI are considered core knowledge at undergraduate medical school level and post-graduate specialization level for Gastroenterologists and General Practitioners.
RESULTS
The overall prevalence of DGBI across Great Britain was 37%, being similar for England (37%), Scotland (33%), and Wales (36%); p = 0.66. There was no difference between English regions (range 33%-43%, p = 0.26). The prevalence of DGBI was highest in those aged 18-40 years (40%), then 40-64 years (37%), and least amongst those ≥65 years (29%); p < 0.001. The most common DGBI were bowel disorders (30%), followed by gastroduodenal (10.5%), anorectal (8.1%) and oesophageal disorders (6.2%). Individuals with DGBI were significantly more likely than those without DGBI to have increased GI-related healthcare visits, medication use, surgical interventions, non-GI somatic symptoms, and reduced quality of life. One-in-three people with DGBI had multiple GI organ regions involved and this correlated with increased health impairment (p < 0.001). The only DGBI mentioned across all medical training curricula is irritable bowel syndrome, while the General Practitioner and Gastroenterology Curricula also recognise the outdated term non-ulcer dyspepsia (as opposed to functional dyspepsia). The 2010 Gastroenterology Curriculum also includes functional constipation and disordered defecation, with the incoming 2022 iteration adding in functional upper GI syndromes, functional abdominal pain, and opioid-induced GI disturbances.
CONCLUSION
Disorders of gut-brain interaction are common across Great Britain and incur substantial health impairment. However, they are generally under-taught within the British medical education system. Increasing awareness and education of disorders of gut-brain interaction might improve patient outcomes.
Identifiants
pubmed: 35781806
doi: 10.1002/ueg2.12271
pmc: PMC9486486
doi:
Substances chimiques
Analgesics, Opioid
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
736-744Informations de copyright
© 2022 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology.
Références
Intern Med J. 2013 Apr;43(4):381-5
pubmed: 22372490
BMJ Neurol Open. 2020 Jun 28;2(1):e000065
pubmed: 33681789
Gastroenterology. 2015 May;148(5):881-5
pubmed: 25805422
Gastroenterology. 2016 Feb 13;:
pubmed: 27144634
Psychosom Med. 2002 Mar-Apr;64(2):258-66
pubmed: 11914441
Lancet Gastroenterol Hepatol. 2018 Apr;3(4):252-262
pubmed: 29396034
Gastroenterology. 2021 Nov;161(5):1670-1688.e7
pubmed: 34331912
Gastroenterology. 2016 May;150(6):1257-61
pubmed: 27147121
United European Gastroenterol J. 2021 Dec;9(10):1178-1188
pubmed: 34599559
Gastroenterology. 2021 Jan;160(1):99-114.e3
pubmed: 32294476
Clin Gastroenterol Hepatol. 2019 Apr;17(5):878-886
pubmed: 29857155
Aliment Pharmacol Ther. 2010 Sep;32(6):811-20
pubmed: 20629976
United European Gastroenterol J. 2022 Sep;10(7):736-744
pubmed: 35781806
Neurogastroenterol Motil. 2022 May 24;:e14410
pubmed: 35608084
Am J Gastroenterol. 2018 Jan;113(1):86-96
pubmed: 29134969
United European Gastroenterol J. 2022 Feb;10(1):126-127
pubmed: 34981671
Expert Rev Gastroenterol Hepatol. 2018 Mar;12(3):215-222
pubmed: 29140124
Gastroenterology. 2020 Apr;158(5):1262-1273.e3
pubmed: 31917991
United European Gastroenterol J. 2021 Dec;9(10):1193-1196
pubmed: 34724358
Am J Gastroenterol. 2018 Feb;113(2):167-169
pubmed: 29206817
Clin Gastroenterol Hepatol. 2020 Feb;18(2):385-391
pubmed: 31154029
J Pediatr Gastroenterol Nutr. 2019 Jun;68(6):806-810
pubmed: 30664565
United European Gastroenterol J. 2015 Feb;3(1):39-52
pubmed: 25653858
United European Gastroenterol J. 2022 Feb;10(1):128-129
pubmed: 34962702
Gut. 2000 Jan;46(1):78-82
pubmed: 10601059
Gastroenterology. 2016 Feb 19;:
pubmed: 27144617